Author Archives: Patricia Inacio PhD

Strongbridge Close to Completing Patient Enrollment for Phase 3 Trial Testing Recorlev for Endogenous Cushing’s Syndrome

More than 70% of patients have been enrolled in Strongbridge Biopharma’s Phase 3 LOGICS clinical trial assessing the safety and effectiveness of Recorlev (levoketoconazole) for treating endogenous Cushing’s syndrome, the company announced. Strongbridge anticipates announcing top-line results from the study before the end of this year and plans to…

PET Scans Help Detect Difficult-to-treat Tumors in Ectopic Cushing’s Syndrome, Study Suggests

Positron emission tomography (PET) scans help identify neuroendocrine tumors causing ectopic Cushing’s syndrome in patients whose disease persisted or recurred after initial treatment, a new study suggests. The research, “68Ga-DOTATOC PET/CT in detecting neuroendocrine tumours responsible for initial or recurrent paraneoplastic Cushing’s syndrome,” was published in the journal…